Technical Analysis for OPTN - OptiNose, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.12 | -2.83% | -0.12 |
OPTN closed down 2.83 percent on Friday, July 10, 2020, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical OPTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Medicine Clinical Medicine Pharmaceutical Organ Systems Disease Inflammation Respiratory Therapy Allergy Glucocorticoids Sinusitis Chronic Rhinosinusitis
Medicine Clinical Medicine Pharmaceutical Organ Systems Disease Inflammation Respiratory Therapy Allergy Glucocorticoids Sinusitis Chronic Rhinosinusitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.66 |
| 52 Week Low | 3.28 |
| Average Volume | 574,287 |
| 200-Day Moving Average | 6.67 |
| 50-Day Moving Average | 5.12 |
| 20-Day Moving Average | 5.92 |
| 10-Day Moving Average | 5.65 |
| Average True Range | 0.76 |
| ADX | 33.13 |
| +DI | 26.36 |
| -DI | 26.88 |
| Chandelier Exit (Long, 3 ATRs ) | 7.71 |
| Chandelier Exit (Short, 3 ATRs ) | 6.21 |
| Upper Bollinger Band | 7.82 |
| Lower Bollinger Band | 4.02 |
| Percent B (%b) | 0.03 |
| BandWidth | 64.27 |
| MACD Line | -0.17 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.3607 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.80 | ||||
| Resistance 3 (R3) | 4.80 | 4.59 | 4.68 | ||
| Resistance 2 (R2) | 4.59 | 4.41 | 4.58 | 4.64 | |
| Resistance 1 (R1) | 4.35 | 4.31 | 4.25 | 4.35 | 4.61 |
| Pivot Point | 4.14 | 4.14 | 4.08 | 4.13 | 4.14 |
| Support 1 (S1) | 3.90 | 3.96 | 3.80 | 3.90 | 3.63 |
| Support 2 (S2) | 3.69 | 3.86 | 3.68 | 3.60 | |
| Support 3 (S3) | 3.45 | 3.69 | 3.56 | ||
| Support 4 (S4) | 3.45 |
